Synthetic surfactants: where are we? Evidence from randomized, controlled clinical trials

ABSTRACT The benefits of exogenous synthetic or animal-derived surfactants for prevention or treatment of respiratory distress syndrome (RDS) are well established. Data from head-to-head

trials comparing animal-derived surfactants primarily with the synthetic surfactant colfosceril suggest that the major clinical advantages afforded by the presence of surfactant protein

(SP)-B and SP-C in animal-derived preparations relate to faster onset of action, a reduction in the incidence of RDS when used prophylactically, and a lower incidence of air leaks and

RDS-related deaths. However, no benefits in terms of overall mortality or BPD have been shown in these head-to-head comparisons. Findings from trials of a new-generation synthetic surfactant

containing a peptide that mimics SP-B, as well as their follow-up study suggest that its administration improves short-term clinical outcomes compared with colfosceril and results in

survival through 1 year of age, which is at least comparable, if not perhaps superior, to that seen with animal-derived surfactants. Access through your institution Buy or subscribe This is

a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 12 print issues and online access $259.00 per

year only $21.58 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated

during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS A RANDOMIZED

CONTROLLED TRIAL OF NEBULIZED SURFACTANT FOR THE TREATMENT OF SEVERE COVID-19 IN ADULTS (COVSURF TRIAL) Article Open access 28 November 2023 AEROSOL, CHEMICAL AND PHYSICAL PROPERTIES OF DRY

POWDER SYNTHETIC LUNG SURFACTANT FOR NONINVASIVE TREATMENT OF NEONATAL RESPIRATORY DISTRESS SYNDROME Article Open access 12 August 2021 USE OF SURFACTANT BEYOND RESPIRATORY DISTRESS

SYNDROME, WHAT IS THE EVIDENCE? Article 08 March 2024 REFERENCES * Ainsworth SB, Milligan DW . Surfactant therapy for respiratory distress syndrome in premature neonates: a comparative

review. _Am J Respir Med_ 2002; 1: 417–433. Article  CAS  PubMed  Google Scholar  * Soll RF, Blanco F . Natural surfactant extract versus synthetic surfactant for neonatal respiratory

distress syndrome. _Cochrane Database Syst Rev_ 2001; (2) Art. No.: CD000144. * Curstedt T, Jörnvall H, Robertson B, Bergman T, Berggren P . Two hydrophobic low-molecular-mass protein

fractions of pulmonary surfactant: characterization and biophysical activity. _Eur J Biochem_ 1987; 168: 255–262. Article  CAS  PubMed  Google Scholar  * Notter RH, Wang Z, Egan EA, Holm BA

. Component-specific surface and physiological activity in bovine-derived lung surfactants. _Chem Phys Lipids_ 2002; 114: 21–34. Article  CAS  PubMed  Google Scholar  * Clark JC, Wert SE,

Bachurski CJ, Stahlman MT, Stripp BR, Weaver TE _et al_. Targeted disruption of the surfactant protein B gene disrupts surfactant homeostasis, causing respiratory failure in newborn mice.

_Proc Natl Acad Sci USA_ 1995; 92: 7794–7798. Article  CAS  PubMed  PubMed Central  Google Scholar  * Nogee LM, Garnier G, Dietz HC, Singer L, Murphy AM, deMello DE _et al_. A mutation in

the surfactant protein B gene responsible for fatal neonatal respiratory disease in multiple kindreds. _J Clin Invest_ 1994; 93: 1860–1863. Article  CAS  PubMed  PubMed Central  Google

Scholar  * Nogee LM, Dunbar III AE, Wert SE, Askin F, Hamvas A, Whitsett JA . Brief report: a mutation in the surfactant protein C gene associated with familial interstitial lung disease. _N

Engl J Med_ 2001; 344: 573–579. Article  CAS  PubMed  Google Scholar  * Cochrane CG, Revak SD . Pulmonary surfactant protein B (SP-B): structure-function relationships. _Science_ 1991; 254:

566–568. Article  CAS  PubMed  Google Scholar  * Moya F, Maturana A . Animal-derived surfactants versus past and present synthetic surfactants: current status. _Clin Perinatol_ 2007; 34:

145–177. Article  PubMed  Google Scholar  * Horbar JD, Wright LL, Soll RF, Wright EC, Fanaroff AA, Korones SB _et al_. A multicenter randomized trial comparing two surfactants for the

treatment of neonatal respiratory distress syndrome. _J Pediatr_ 1993; 123: 757–766. Article  CAS  PubMed  Google Scholar  * Sehgal SS, Ewing CK, Richards T, Taeusch HW . Modified bovine

surfactant (Survanta) versus a protein-free surfactant (Exosurf) in the treatment of respiratory distress syndrome in preterm infants: a pilot study. _J Natl Med Assoc_ 1994; 86: 46–52. CAS

  PubMed  PubMed Central  Google Scholar  * Vermont-Oxford Neonatal Network. A multicenter, randomized trial comparing synthetic surfactant with modified bovine surfactant extract in the

treatment of neonatal respiratory distress syndrome. _Pediatrics_ 1996; 97: 1–6. Google Scholar  * Modanlou HD, Beharry K, Padilla G, Norris K, Safvati S, Aranda JV . Comparative efficacy of

Exosurf and Survanta on early clinical course of respiratory distress syndrome and complications of prematurity. _J Perinatol_ 1997; 17: 455–460. CAS  PubMed  Google Scholar  * da Costa DE,

Pai MGK, Al Kusaiby SM . Comparative trial of artificial and natural surfactants in the treatment of respiratory distress syndrome of prematurity: experiences in a developing country.

_Pediatr Pulmonol_ 1999; 27: 312–317. Article  CAS  PubMed  Google Scholar  * Moya FR, Gadzinowski J, Bancalari E, Salinas V, Kopelman B, Bancalari A _et al_., for the International Surfaxin

Collaborative Study Group. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among

very preterm infants. _Pediatrics_ 2005; 115: 1018–1029. Article  PubMed  Google Scholar  * Hudak ML, Martin DJ, Egan EA, Matteson EJ, Cummings J, Jung AL _et al_. A multicenter randomized

masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome. _Pediatrics_ 1997; 100: 39–50. Article  CAS 

PubMed  Google Scholar  * Hudak ML, Farrell EE, Rosenberg AA, Jung AL, Auten RL, Durand DJ _et al_. A multicenter randomized, masked comparison trial of natural versus synthetic surfactant

for the treatment of respiratory distress syndrome. _J Pediatr_ 1996; 128: 396–406. Article  CAS  PubMed  Google Scholar  * Kukkonen AK, Virtanen M, Järvenpää A-L, Pokela ML, Ikonen S,

Fellman V . Randomized trial comparing natural and synthetic surfactant: increased infection rate after natural surfactant? _Acta Paediatr_ 2000; 89: 556–561. Article  CAS  PubMed  Google

Scholar  * Ainsworth SB, Beresford MW, Milligan DWA, Shaw N, Matthews J, Fenton A _et al_. Pumactant and poractant alfa for treatment of respiratory distress syndrome in neonates born at 25

to 29 weeks' gestation: a randomised trial. _Lancet_ 2000; 355: 1387–1392. Article  CAS  PubMed  Google Scholar  * Andersson S, Kheiter A, Merritt TA . Oxidative inactivation of

surfactants. _Lung_ 1999; 177: 179–189. Article  CAS  PubMed  Google Scholar  * Revak SD, Merritt TA, Cochrane CG, Heldt GP, Alberts MS, Anderson DW _et al_. Efficacy of synthetic

peptide-containing surfactant in the treatment of respiratory distress syndrome in preterm infant rhesus monkeys. _Pediatr Res_ 1996; 39: 715–724. Article  CAS  PubMed  Google Scholar  *

Cochrane CG, Revak SD, Merritt TA, Heldt GP, Hallman M, Cunningham MD _et al_. The efficacy and safety of KL4-surfactant in preterm infants with respiratory distress syndrome. _Am J Respir

Crit Care Med_ 1996; 153: 404–410. Article  CAS  PubMed  Google Scholar  * Sinha SK, Lacaze-Masmonteil T, Valls i Soler A, Wiswell TE, Gadzinowski J, Hajdu J _et al_., for the Surfaxin

Therapy Against Respiratory Distress Syndrome Collaborative Group. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very preterm infants at high risk

for respiratory distress syndrome. _Pediatrics_ 2005; 115: 1030–1038. Article  PubMed  Google Scholar  * Moya F, Sinha S, Gadzinowski J, D'Agostino R, Segal R, Guardia C _et al_. SELECT

and STAR Study Investigators. One-year follow up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: results from 2 multicenter, randomized,

controlled trials. _Pediatrics_ 2007; 119: e1361–e1370. Article  PubMed  Google Scholar  * Kattwinkel J . Synthetic surfactants: the search goes on. _Pediatrics_ 2005; 115: 1075–1076.

Article  PubMed  Google Scholar  * Halliday HH . Surfactants: past, present and future. _J Perinatol_ 2008; 28: S47–S56. Article  CAS  PubMed  PubMed Central  Google Scholar  * Engle WA, the

Committee on Fetus and Newborn. Surfactant-replacement therapy for respiratory distress in the preterm and term neonate. _Pediatrics_ 2008; 121: 419–432. Article  PubMed  Google Scholar 

Download references AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Department of Neonatology, New Hanover Regional Medical Center, Wilmington, NC, USA F Moya * Department of Pediatrics,

University of North Carolina, Chapel Hill, NC, USA F Moya Authors * F Moya View author publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR

Correspondence to F Moya. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Moya, F. Synthetic surfactants: where are we? Evidence from randomized,

controlled clinical trials. _J Perinatol_ 29 (Suppl 2), S23–S28 (2009). https://doi.org/10.1038/jp.2009.26 Download citation * Published: 28 April 2009 * Issue Date: May 2009 * DOI:

https://doi.org/10.1038/jp.2009.26 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently

available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative KEYWORDS * surfactant * respiratory distress syndrome * bronchopulmonary

dysplasia * infant/newborn